Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics, Inc. will report its first quarter 2024 financial results and operational updates during a conference call on May 9, 2024. The company focuses on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, with programs like FT819 and FT522. The event coincides with the American Society of Gene and Cell Therapy 27th Annual Meeting.
Fate Therapeutics announced preclinical data for its FT522 program for autoimmune diseases at the ASGCT Annual Meeting. FT522, a CD19-targeted CAR NK cell product candidate, showed promising results in depleting SLE donor B cells and eliminating host immune cells. The ADR technology incorporated into FT522 enhances its potency, potentially offering a new treatment approach for autoimmune diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.